Free Trial
→ This Signal Only Flashes Once Every 4 Years – And It Just Triggered (From Crypto Swap Profits) (Ad)
NASDAQ:RANI

Rani Therapeutics Q3 2023 Earnings Report

Rani Therapeutics logo
$0.58 -0.04 (-6.66%)
Closing price 04:00 PM Eastern
Extended Trading
$0.59 +0.01 (+1.17%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Rani Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Rani Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rani Therapeutics Announcement Details

Quarter
Q3 2023
Date
11/8/2023
Time
N/A
Conference Call Date
Wednesday, November 8, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Rani Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Rani Therapeutics' Q3 2023 Quarterly reportQuarterly report
(10-Q)

Rani Therapeutics Earnings Headlines

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Average PT from Analysts
May 27 at 3:49 AM | americanbankingnews.com
Q3 Earnings Forecast for RANI Issued By Zacks Small Cap
May 23, 2025 | americanbankingnews.com
While others chase AI stocks, smart traders do this
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
May 29, 2025 | WealthPress (Ad)
Brokers Offer Predictions for RANI Q2 Earnings
May 23, 2025 | americanbankingnews.com
Rani Therapeutics strikes deal to issue new warrants
May 21, 2025 | uk.investing.com
RANI: 1Q:25 Financial Results
May 20, 2025 | finance.yahoo.com
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

View Rani Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles